Baidu
map

Chest:慢性阻塞性肺疾病患者血清sirtuin-1下降

2017-05-19 xing.T MedSci原创

由此可见,血清中SIRT1(s120s)在COPD患者中有所降低,可能反映了降低了氧化应激细胞内的SIRT1,并可能作为COPD某些疾病特征的潜在生物标志。

蛋白去乙酰化酶sirtuin-1(SIRT1)是一种抗衰老分子,在慢性阻塞性肺疾病(COPD)患者的肺脏中有所降低。近日,据报道血清中可以检测出SIRT1,但COPD患者血清中SIRT1水平尚未被报道。

研究人员通过Western blot方法测定了血清SIRT1,并通过阳性对照计算出了蛋白条带灰度值的相对比值。

通过Western blot方法定量的SIRT1有几个不同大小的分子量,包括120kda(实际大小)和片段(102、75kda)。其中,只有120kda血清SIRT1(s120s)在COPD患者中显著降低,相比于对照组无COPD的患者(健康者s120s比值:0.90±0.34 vs. COPD患者:0.68±0.24;P=0.014),并与气道阻塞(FEV1/FVC;R=0.31;P=0.020)及其预测的FEV1%测量的COPD严重程度呈正相关(R=0.29;P=0.029)。血清s120s也表现出与体重指数(R=0.36;P=0.0077)和肺脏每单位体积的扩散能力呈正相关(R=0.32;P=0.025)。它也随着肺气肿严重程度(R=-0.40,P=0.027)和频繁COPD恶化的临床病史(不频繁:0.76±0.20 vs. 频繁:0.56±0.26;P=0.027)明显降低。在正常培养条件下的A549细胞和原代上皮细胞的上清液中没有检测到SIRT1。

由此可见,血清中SIRT1(s120s)在COPD患者中有所降低,可能反映了降低了氧化应激细胞内的SIRT1,并可能作为COPD某些疾病特征的潜在生物标志。

原始出处:

Satoru Yanagisawa.et al.Decreased serum sirtuin-1 in chronic obstructive pulmonary disease.chest.2017.http://journal.publications.chestnet.org/article.aspx?articleid=2628645

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1929341, encodeId=600f19293419f, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Jan 23 14:40:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050696, encodeId=c49b205069618, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Sep 23 10:40:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798980, encodeId=13d11e989802e, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jan 21 01:40:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696719, encodeId=b15b1696e1988, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Aug 03 12:40:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199931, encodeId=fef119993161, content=谢谢!学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuMjuyhtoVWeR6wicZJ7x8aibA0uJx3pbrjm7BTuyrYobGwEK0icaWCga5ZMYujQH8icUM2pLTGVCST8Q/0, createdBy=d70c1956706, createdName=mayio, createdTime=Fri May 19 09:36:38 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199885, encodeId=6f93199885a1, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Fri May 19 08:04:51 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
    2018-01-23 Smile2680
  2. [GetPortalCommentsPageByObjectIdResponse(id=1929341, encodeId=600f19293419f, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Jan 23 14:40:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050696, encodeId=c49b205069618, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Sep 23 10:40:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798980, encodeId=13d11e989802e, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jan 21 01:40:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696719, encodeId=b15b1696e1988, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Aug 03 12:40:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199931, encodeId=fef119993161, content=谢谢!学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuMjuyhtoVWeR6wicZJ7x8aibA0uJx3pbrjm7BTuyrYobGwEK0icaWCga5ZMYujQH8icUM2pLTGVCST8Q/0, createdBy=d70c1956706, createdName=mayio, createdTime=Fri May 19 09:36:38 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199885, encodeId=6f93199885a1, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Fri May 19 08:04:51 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1929341, encodeId=600f19293419f, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Jan 23 14:40:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050696, encodeId=c49b205069618, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Sep 23 10:40:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798980, encodeId=13d11e989802e, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jan 21 01:40:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696719, encodeId=b15b1696e1988, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Aug 03 12:40:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199931, encodeId=fef119993161, content=谢谢!学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuMjuyhtoVWeR6wicZJ7x8aibA0uJx3pbrjm7BTuyrYobGwEK0icaWCga5ZMYujQH8icUM2pLTGVCST8Q/0, createdBy=d70c1956706, createdName=mayio, createdTime=Fri May 19 09:36:38 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199885, encodeId=6f93199885a1, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Fri May 19 08:04:51 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1929341, encodeId=600f19293419f, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Jan 23 14:40:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050696, encodeId=c49b205069618, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Sep 23 10:40:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798980, encodeId=13d11e989802e, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jan 21 01:40:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696719, encodeId=b15b1696e1988, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Aug 03 12:40:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199931, encodeId=fef119993161, content=谢谢!学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuMjuyhtoVWeR6wicZJ7x8aibA0uJx3pbrjm7BTuyrYobGwEK0icaWCga5ZMYujQH8icUM2pLTGVCST8Q/0, createdBy=d70c1956706, createdName=mayio, createdTime=Fri May 19 09:36:38 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199885, encodeId=6f93199885a1, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Fri May 19 08:04:51 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
    2017-08-03 tomyang96
  5. [GetPortalCommentsPageByObjectIdResponse(id=1929341, encodeId=600f19293419f, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Jan 23 14:40:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050696, encodeId=c49b205069618, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Sep 23 10:40:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798980, encodeId=13d11e989802e, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jan 21 01:40:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696719, encodeId=b15b1696e1988, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Aug 03 12:40:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199931, encodeId=fef119993161, content=谢谢!学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuMjuyhtoVWeR6wicZJ7x8aibA0uJx3pbrjm7BTuyrYobGwEK0icaWCga5ZMYujQH8icUM2pLTGVCST8Q/0, createdBy=d70c1956706, createdName=mayio, createdTime=Fri May 19 09:36:38 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199885, encodeId=6f93199885a1, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Fri May 19 08:04:51 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
    2017-05-19 mayio

    谢谢!学习了!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1929341, encodeId=600f19293419f, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Jan 23 14:40:00 CST 2018, time=2018-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050696, encodeId=c49b205069618, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Sep 23 10:40:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798980, encodeId=13d11e989802e, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jan 21 01:40:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696719, encodeId=b15b1696e1988, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Aug 03 12:40:00 CST 2017, time=2017-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199931, encodeId=fef119993161, content=谢谢!学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuMjuyhtoVWeR6wicZJ7x8aibA0uJx3pbrjm7BTuyrYobGwEK0icaWCga5ZMYujQH8icUM2pLTGVCST8Q/0, createdBy=d70c1956706, createdName=mayio, createdTime=Fri May 19 09:36:38 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199885, encodeId=6f93199885a1, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Fri May 19 08:04:51 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
    2017-05-19 榄枷檬

    谢谢分享

    0

相关资讯

Am J Respir Crit Care Med:COPD患者肺功能预后的评估新进展

慢性阻塞性肺疾病(COPD)患者肺功能的下降速率,比同年龄的正常人的下降速率更快,即使是在患者戒烟后,其下降速率仍比正常人快。处于肺气肿附近的正常肺组织,在人呼吸时会受到异常的拉伸,这种生物学应力可影响肺气肿的发生和发展。近期,Am J Respir Crit Care Med杂志中一篇文章提出,使用CT来量化这种肺局部的风险,对其FEV1的下降风险进行预测。该研究者选取了680名受试者,采用配对

CHEST:FEV1的改善与减少COPD急性加重密切相关!

目前,临床使用的各类药物降低COPD加重风险的机制尚不清楚。近期,一项发表在杂志CHEST上的研究评估了通过1秒用力呼气量(FEV1)检测的气道通畅改善水平是否与疾病的急性加重风险降低相关。通过系统评估,研究者们确定了治疗前FEV1(dFEV1)的变化和中度至重度COPD急性发作的频率。使用Meta回归分析,研究者们生成了一个以dFEV1作为调节变量,急性加重率(RD)、恶化率(RR)或风险比(H

Thorax:慢性阻塞性肺疾病吸烟者服用伐尼克兰和安非他酮的心血管和神经精神风险如何?

由此可见,在慢性阻塞性肺病的吸烟者中,相比于NRT,伐尼克兰和安非他酮似乎与心血管事件、抑郁或自我伤害的风险增加不存在相关性。

Chest:降低COPD恶化风险与FEV1的改善相关!

该研究的结果表明,FEV1增加与较低COPD恶化风险显著相关,提示气道通畅是这一效应的一个重要机制。

药补不如食补! 饮食习惯如何改善机体健康 降低多种疾病的发生风险?

我们都知道,摄入过多“错误”的食物会诱发体重增加,并且引起肥胖,比如一些高能量低营养的食物,包括快餐、加工食品和外卖食品等;这些食物通常都富含大量的饱和脂肪酸、精致碳水化合物、糖类和钠类,其能够增加个体患糖尿病、心脏病以及某些癌症的风险。 但饮食不良往往也会引起很大的影响,近来研究人员就通过研究来理解不健康的饮食习惯如何影响机体肺部的

Lancet Respir Med:强力霉素对COPD急性加重期治疗无效

对于轻中重度COPD患者,口服强力霉素不能缓解患者的疾病恶化进程,该研究结果不支持在慢性阻塞性肺病急性加重期使用抗生素

Baidu
map
Baidu
map
Baidu
map